Thank you, everyone. Brian, and welcome,
of The important the start new in will of XXXX second Insmed's quarter an biotechnology mid-cap era down go history company. as as a
data positive most II the results of course, in ARIKAYCE successful the Phase lung TPIP and, saw but growth not ASPEN continued of this only also we study. the During quarter, refractory MAC and significantly, disease, landmark of for PH-ILD
us it of the physicians and work to celebrate and to is time patients, so to field investors. that with grateful rewarding a are We able moment mark be It biotechnology. why is reminds in this
focus Today, on all our exciting of number pillars. across a I of catalysts to intend
it aware on opportunity such that us. the keenly holds more important are believe is can right, to bronchiectasis. of that than get executing will brensocatib again, launch our to which company a transform flawlessly near that If executing continue this medium-term we why for we and nothing once success the focus we potential in for However, is be
with So brensocatib. World in positive of ASPEN July short update an was of start results let Bronchiectasis me celebration a study. nothing Conference in Scotland from the there The Dundee, the held on
We these reiterate by have to and are CHEST life-changing been in the so October study, additional to releasing has be believe shown have at physicians be emotional the data who patients honored them subgroups data, something from look the responses that enthusiastic the bronchiectasis. of heard not the touched the while conference ASPEN's We data for these often exacerbations improve ASPEN also good any want to in Brensocatib the results. and overwhelmingly to and safety there not we've surprises we a positive reduce trial function the forward profile ability of including treat living Boston.
I demonstrated pulmonary displaying when with lung preserve consistency potential only the was subpopulation results negative to prespecified to with feel that presented. patients patients to but overall comparable placebo, rate all and how is from that should
it be if proud immensely possible. hands are a of type as for of brensocatib forward And as to the to breakthrough of those into quickly part We we this patients. getting approved, need look who
even on brensocatib for schedule. of filing expected prepare bronchiectasis of that goal quarter slightly our in the remains U.S. the or We fourth year, of ahead progress toward continue and to this in
so in large all already us. the of gating there no clinical the have Importantly, left for factors completed, and preclinical filing of necessary data front required been are
the those results approval. final an are determination one focused including As whether making will for on on represents and set, the data trial know, documenting enormous we doses you the thoroughly or we filing, file ASPEN both for
next anticipate of to in the in launch continue U.S. middle the We a year.
been also that add force and Nearly pool reps sales has for these more have the already team were X,XXX U.S. to commercial from sales accepted diligently intend expected the preparing Our a we launch. to resumes. additional all XXX offers, than of chosen of
deployment and proactive those in have the into reps contributed a expect put the XXX reps this to approach of ARIKAYCE launches. to XX we ahead reps approval, X the We top ARIKAYCE pattern of This all that We and field in launch. field months rare disease the timeline follows ranking of sales believe year. non-oncology by similar new the trained as October sales for of
field to also the detailing brensocatib, patients can in while awareness intend will ARIKAYCE For state education from they where on hopes we even that have physicians more the who helping and of reps work to benefit earlier treatment. disease in
lives made with disease of In on receptive via already. been have close discussions regional and payers about disease state by permanent engaged addition, national the we exacerbations. to and damage have patient bronchiectasis and to XX% great progress payer learning both Payers the have U.S. education caused
ASPEN request already filing follow Our and quarter. next medical detailed pre-approval upon NDA team the data our sharing reactively will more is discussions
is position with inventory year already API it note anticipated important to next in a in the very Finally, our that perspective from we of in hand. good are context a ample launch supply
converted at enough of brensocatib that into through meet the for to form of U.S. have to tablet the anticipated least by its of expect first the this we current end fact, API our launch. demand year year, in In
establish brensocatib of that safety a and to we global a Even supply on to prioritize supply always steady we sufficient large a of allowed notice and to by matter chains for of supply supply policy, in of a our inventory meaningful continuity to pandemic establishing that during robust well backup quantities chains, is was ARIKAYCE, is make stock easier respiratory and and though work inventory. shorter underway. build compared look intend patients. even It us As that ARIKAYCE to maintain principle
bronchiectasis. beyond Moving
CRS we expect in study XXXX. which polyps, of out without read second encouraged our progress half to continue to the of We be the Phase nasal by ongoing II in
the study, nonetheless. data be appear to data the to that which We symptom correspond and scores see NSP occurring. continue acknowledge should that is we the We but from it find in still with time encouraging inhibition improvements reduction blinded in when DPPX average early, from blinded
are end the We suppurativa, U.S. We has thereafter. shortly to potential to DPPX the year with screened the stated ASPEN be moving study have forward study off excited that our first kick the on with brensocatib II previously hidradenitis first Phase the the of sites before the being track demonstrated a of mechanism. remain patients open to and active plans of now
This to work maintain work are an not class we develop our having to the begun next-generation briefly the out. Phase this DPPX inhibitors is Finally, comment after in doing on of new in first leadership I important want effort read shortly new, II to WILLOW medicines. results
have already and unique and inhibitors novel XXX over compounds. and filed have synthesized applications we over patent that disclose DPPX screened fact, In XX claim these
inflammatory where be are Keep continue these such other treatments mind We could from evaluating we candidate we for rheumatoid data patients explore as arthritis, molecules class. in follow-on those IND-enabling we new expect sell conditions. compounds DPPX Either lupus follow presence are we could needs drug using ASPEN a and more now or group patients expected and to indications forefront and unmet first nephritis one safety despite the others the the can exciting to are from at X this in advancing indications want to in neutrophil who we significant include involvement with the to bronchiectasis, if way, these markets. efficacy closely This to of ourselves that partner other studies, there face strength choose to them may indications these current new significant already keep us have on and other into of this inhibition. with or develop thereafter.
Based with
to report am that XX% to commercially, second turn perform compared continues will are brensocatib, quarter in Much this me success year. that ARIKAYCE the the well approvals I to of assuming of growth our world. the let same strong ones delivering that launch ARIKAYCE. across the directly teams execution to Now achieved. to related teams to regulatory quarter last be commercial Keep mind these pleased is
quarter. ARIKAYCE's this commercial progress to also addition development In have on execution, made we clinical
the division us lung with As measures. endpoint data with the previously the ENCORE for That in study aligning in positive. expansion June refractory support full the the patients indicated, patient-reported FDA successfully indication outcome meeting approval for can resulted all that of responsible are the MAC label we if the include primary for met current FDA on to and
have point. updated chance conservative with the more patients, Based of this have clarity ensuring enrollment target ENCORE's the FDA, which to than we we enrollment assumptions. study the achieving target its targets the of goal evaluation, that objectives, from reevaluated on that success we in for powering we appropriately have XX% give Now of best XXX using ENCORE's end the primary powering
trial very for study the Importantly, has proceeding ARISE XXXX following result. recruitment the well been throughout
As screening expect be would first out quarter read expect then the in for in a patients ENCORE position a line stop in result, top and new to quarter to to we the third later the of results XXXX.
possibility Subpart we As accelerated about filing FDA H. of we now before, an approach commented have under the the can
We expect year. to this that of end answer have the by
with for ENCORE global all required our to ARIKAYCE to MAC potentially the regulatory reminder, all continues be expectation filings a will disease. include label for the lung that As patients be data expand to
from more interactions with We FDA. will we you learn the our update as
in Let from XXXX. trial, recently, readout readout which second have now half completed our Phase me in Phase likely also on the We has provide May. an PAH in update II also on our than PH-ILD PAH II study for TPIP development the XX% the strong accelerated of keeps in our Enrollment in of quick a program. enrollment us trial resulting more expected track
monitoring not have the the show study of on reductions in in many which consistently for who PVR to impressive the pulmonary are their vascular a improvements in resistance normally not blinded therapy. expected We basis, had be continue study. results change patients These patients would for the a in of
represents patients, the important launch to summarize type our including of is This is profile year, only of for top and a for diligently bronchiectasis today's recognize and filings, line discussions progressing how investors enormity to the and potentially PH-ILD commercial it comes lies once that preparing inventory which other payer upcoming stakeholders. planning, Insmed the for update, next this. ahead adds it is us the lucky. opportunity emerge and regulatory get the our ahead of began along We of you're with right is career, the brensocatib if or what compelling the it in on all I for this schedule. in all to of All recent of launch trial can readout of results.
If excitement expected readiness, that for
nasal II ahead period execute without right followed and own stakeholders of progress we readouts their remarkable our brensocatib III we polyps such across enter While we making acknowledge to this sizable the We brensocatib, Shortly of in development in of the forward successful the of as patients research, CRS MAC and clinical in to of work critical has importance and Phase also us. parallel are infection. opportunities of the growth we the readout anticipate area the TPIP the for and lies lung launched that ARIKAYCE launch that continuing to newly brensocatib, could on readouts that as of other after behalf represent potential Phase potential unique and by look clinical want opportunities growth additional we I diagnosed every and unlock. to exciting recognize PAH
turn the will the to over the quarter. Now to I for through call walk financials Sara
